<DOC>
	<DOCNO>NCT01310413</DOCNO>
	<brief_summary>This study ass safety immunogenicity GSK Biologicals ' H5N1 flu candidate vaccine GSK1557484A child 6 month &lt; 18 year age .</brief_summary>
	<brief_title>Monovalent H5N1 Vaccine GSK1557484A Children 6 Months &lt; 18 Years Age</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male female child &gt; = 6 month &lt; 18 year age time first vaccination . Written inform consent obtain subject 's parent/guardian . Documentation assent child 9 &lt; 18 year age ( deemed mandatory local practice ) . Satisfactory baseline medical assessment history physical examination Parent/guardian subject access consistent mean telephone contact , land line mobile , NOT pay phone multipleuser device . Parents/guardians subject investigator believe understand requirement protocol comply . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential must practice adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception 2 month completion vaccination series . Medical history physicianconfirmed infection H5N1 virus . Previous vaccination time H5N1 vaccine . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine/product , plan use study period . Presence significant acute chronic , uncontrolled medical psychiatric illness . Presence neurological psychiatric diagnosis , although stable , deemed investigator render potential subject parent/guardian unable/unlikely provide accurate safety report . Evidence current subject parent/guardian substance abuse , include alcohol , medical history . Presence temperature &gt; = 38.0ºC method , acute symptom great `` mild '' severity schedule date first dose . Diagnosed cancer , treatment cancer , within 3 year . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . Receipt systemic glucocorticoid within 1 month prior first dose test article cytotoxic immunosuppressive drug within 6 month prior first dose test article . Receipt immunoglobulins and/or blood product within 3 month first test article administration plan administration product study period . Any significant disorder coagulation treatment warfarin derivative heparin . An acute evolve neurological disorder history GuillainBarré syndrome within 6 week receipt seasonal influenza vaccine . Administration inactivate seasonal influenza vaccine within 14 day , live , attenuate seasonal influenza vaccine within 30 day first test article dose , vaccine ( ) foreseen study protocol within 30 day first test article dose . Planned administration vaccine ( ) foreseen study protocol completion `` Day 42 '' visit . Any known suspected allergy constituent influenza vaccine history severe reaction previous influenza vaccination . Known pregnancy , positive urine pregnancy test result prior test article dose . Lactating nursing . Child care .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Influenza</keyword>
	<keyword>H5N1</keyword>
	<keyword>Pandemic</keyword>
</DOC>